Clinical Trial: A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

U.S., July 12 -- ClinicalTrials.gov registry received information related to the study (NCT07061574) titled 'A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes' on July 02.

Brief Summary: This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to <21 with recent-onset stage 3 T1D.

Study Start Date: Oct. 15, 2025

Study Type: INTERVENTIONAL

Condition: Type 1 Diabetes New Onset

Intervention: DRUG: Anti-thymocyte globulin (ATG)

ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation....